Economic evaluation of third-line treatment with alemtuzumab for chronic lymphocytic leukaemia

Clinical Drug Investigation

Volumn 27, Issue 11, 2007, Pages 755-764

  Scott, W Guy ^a,b,c   Scott, Helen M ^a  

^a ScottEconomics   (New Zealand)

^b MASSEY UNIVERSITY   (New Zealand)

^c Kilbirnie   (New Zealand)

Author keywords

Alemtuzumab, therapeutic use; Chronic lymphocytic leukaemia; Cost analysis; Cost effectiveness

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; CHLORPHENIRAMINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; FLUDARABINE; ONDANSETRON; PARACETAMOL; RITUXIMAB;

ARTICLE; BLOOD TOXICITY; CHRONIC LYMPHATIC LEUKEMIA; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG FEVER; HUMAN; INFECTION; NEUTROPENIA; NEW ZEALAND; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 34948836666     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200727110-00002     Document Type: Article

References (32)

1. Oscier D, Fegan C, Hillmen P, et al. Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. Br J Haematol 2004 May; 125: 294-317
2. Gale RP, Cozen W, Goodman MT, et al. Decreased chronic lymphocytic leukemia incidence in Asians in Los Angeles County. Leuk Res 2000 Aug; 24 (8): 665-9
3. New Zealand Health Information Service. Cancer registrations and deaths 2002. New Zealand Ministry of Health, 2002
4. Data on file, latest registration figures for lymphocytic leukaemia. Wellington: New Zealand Health information Service, 2007
5. Everybody: health information for New Zealanders. Leukemia [online]. Available from URL: http://www.everybody.co.nz [Accessed 2007 Aug 13]
6. Keating MJ, Chiorazzi N, Messmer B, et al. Biology and treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2003: 153-75
7. Algorithm for patients with CLL requiring treatment. Auckland: Auckland District Health Board, 2007: 1
8. Robak T. Alemtuzumab in the treatment of chronic lymphocytic leukemia. BioDrugs 2005; 19 (1): 9-22
9. Keating M, Coutre S, Rai K, et al. Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma 2004 Mar; 4 (4): 220-7
10. Drummond MF, O'Brien BJ, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. New York and Toronto: Oxford University Press, 1997
11. Thompson S, van Nooten F, van Agthoven M, et al. Cost and cost-effectiveness of FluCam versus FCR in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). 11th Congress of the European Haematology Association; 16-18 June 2006, Amsterdam
12. Thompson S, van Nooten F, van Agthoven M, et al. Cost-effectiveness of alemtuzumab (MabCampath®) in patients with B-cell chronic lymphocytic leukemia (CLL) who have failed alkylating agents and fludarabine. 11th Congress of the European Haematology Association; 16-18 June 2006, Amsterdam
13. Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005 Jun 20; 23 (18): 4070-8
14. New Zealand pharmaceutical schedule. Wellington, New Zea-land: PHARMAC (Pharmaceutical Management Agency), 2006 Aug
15. Data on file, New Zealand Health Information Service. Inpatient national prices. Wellington: New Zealand Health Information Service, 2006
16. New Zealand Ministry of Health. Hospital throughput 2002/03 [online]. Available from URL: http://www.moh.govt.nz [Accessed 2007 Aug 13]
17. Southern Cross Medical Care Society. VIP Plan 4 Schedule of benefits [online]. Available from URL: http://www.southerncross.co.nz/ [Accessed 2007 Aug 13]
18. Data on file, prices of saline, giving set, syringes, IV venflon. Christchurch, New Zealand: Ebos, 2006
19. Laboratory test purchase list. Wellington, New Zealand: Central Regional Health Authority, 1997
20. Commerce Commission. Commerce Act 1986: Business Acquisition Section 66. Notice Seeking Clearance: New Zealand Diagnostic Group Ltd & Sonic Healthcare (New Zealand) Ltd [online]. Available from: http://www.comcom.govt.nz [Accessed 2007 Aug 13]
21. Fraser G, Smith CA, Imrie K, et al. Alemtuzumab in chronic lymphocytic leukemia: a clinical practice guideline. Cancer Care Ontario; 2006 June 14. Report no.: 6-16: Section 1
22. Wierda W, O'Brien S, Faderl S, et al. A retrospective comparison of three sequential groups of patients with recurrent/refractory chronic lymphocytic leukemia treated with fludarause bine-based regimens. Cancer 2006; 106 (2): 337-45
23. Reserve Bank of New Zealand. Exchange rates and foreign exchange turnover, selected exchange rates and foreign execonomic change turnover data for selected currencies, B1 Exchange rates: bilateral rates and TWI [online]. Available from URL: http://www.rbnz.govt.nz/statistics/exandint/b1/ [Accessed 2007 Aug 13]
24. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002 May 15; 99 (10): 3554-61
25. Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002 Sep 15; 20 (18): 3891-7
26. Keating MJ, O'Brien S, Kontoyiannis D, et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002; 43 (9): 1755-62
27. Zikmund WG. Business research methods. Fort West: Harcourt Brace College Publishers, 2000
28. Devlin N, Hanson P, Kind P. The health state preferences and logical inconsistencies of New Zealanders: a tail of two tariffs. Heslington: University of York Centre for Health Economics, University of York. Working papers, 2000: 180
29. Grunberg SM, Srivastava A, Grunberg KJ, et al. Intensity of chemotherapy-induced emesis and overall survival as determinants of a global utility score. Support Care Cancer 2002 Nov; 10 (8): 624-9
30. Norum J, Angelsen V, Wist E, et al. Treatment costs in Hodgkin's disease: a cost-utility analysis. Eur J Cancer 1996 Aug; 32A (9): 1510-7
31. Wang XQ, Lin GW. Study on the quality of life in long-term survivors with acute leukemia in Shanghai [in Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi 2003 Nov; 24 (11): 1049-51
32. @Risk version 4.5. Risk analysis and simulation add-in for Microsoft Excel. Newfield (NY): Palisade Corporation, 2004